| Lifespan Medical Services Llc | |
|
1125 Forrest Ave Dover DE 19904-3483 | |
| (302) 346-0100 | |
| (302) 346-0103 |
| Full Name | Lifespan Medical Services Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 1125 Forrest Ave, Dover, Delaware |
| Authorized Official Name and Position | Harsha Tankala (OWNER/PRESIDENT) |
| Authorized Official Contact | 3026780950 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lifespan Medical Services Llc 1125 Forrest Ave Dover DE 19904-3483 Ph: (302) 346-0100 | Lifespan Medical Services Llc 1125 Forrest Ave Dover DE 19904-3483 Ph: (302) 346-0100 |
| NPI Number | 1427131382 |
|---|---|
| Provider Enumeration Date | 10/23/2006 |
| Last Update Date | 06/21/2018 |
| Medicare PECOS PAC ID | 0143323493 |
|---|---|
| Medicare Enrollment ID | O20070307000376 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427131382 | NPI | - | NPPES |
| 1000041898 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | C1-0005962 (Delaware) | Primary |
| Provider Name | Harsha Tankala |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164441242 PECOS PAC ID: 7416900675 Enrollment ID: I20050228000686 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
| Provider Name | Claudia Pierce |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770847402 PECOS PAC ID: 8022265297 Enrollment ID: I20140424001335 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
| Provider Name | Candace E Finch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891334231 PECOS PAC ID: 4183045818 Enrollment ID: I20200604000444 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
| Provider Name | Kaitlin Marie Fielder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962001180 PECOS PAC ID: 1658787171 Enrollment ID: I20210309000571 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
| Provider Name | Erin P Beaudry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083859383 PECOS PAC ID: 0143369371 Enrollment ID: I20230515000134 |
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
News Archive
Omeros Corporation today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement. OMS302 is the company's proprietary Pharmacosurgery product being developed for all ILR, including cataract surgery and refractive lens exchange.
Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU's Institute for Advancing Medical Innovation.
› Verified 5 days ago
Middletown Wellness Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Federal St, Dover, DE 19901 Phone: 302-744-4849 Fax: 302-739-6627 | |
Northeast Family Planning Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Federal St, Dover, DE 19901 Phone: 302-744-4548 Fax: 302-739-1613 | |
Kent Epsdt Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Federal St, Dover, DE 19901 Phone: 302-744-4548 Fax: 302-739-1613 | |
Natwarlal V Ramani Md Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 742 S Governors Ave, Suite 3, Dover, DE 19904 Phone: 302-678-5008 Fax: 302-678-5505 | |
Lee Dennis, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 960 Forest St, Dover, DE 19904 Phone: 302-735-1888 | |
Dph Seaford Family Planning Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Federal St, Dover, DE 19901 Phone: 302-744-4548 Fax: 302-739-1613 | |
Cdw South Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Federal St, Dover, DE 19901 Phone: 302-744-4548 Fax: 302-739-1613 |